Guillain-Barre syndrome is suggested by the presence of progressive peripheral polyneuropathy with hyporeflexia. This syndrome typically presents as a symmetrical polyneuropathy that develops rapidly and is often preceded by an infection. It initially causes paraesthesia and lower limb weakness, which can quickly spread to involve the upper limb, cranial nerves, autonomic function, and respiratory function. As it is a disorder of the peripheral nervous system, it presents with lower motor neurone signs such as hyporeflexia.

Amyotrophic lateral sclerosis, on the other hand, is a disorder of the motor neurones and doesn’t typically cause sensory disturbance such as paraesthesia. It often has a slower onset.

Multiple sclerosis affects the central nervous system and therefore presents with upper motor neurone signs such as hyperreflexia.

Myasthenia gravis is a neuromuscular junction disorder that is characterized by fatiguability and doesn’t typically cause sensory disturbance.

Although the features of transverse myelitis and Guillain-Barre can overlap and coexist, the absence of a sensory level on examination makes transverse myelitis less likely in this case.

Guillain-Barre Syndrome: A Breakdown of its Features

Guillain-Barre syndrome is a condition that occurs when the immune system attacks the peripheral nervous system, resulting in demyelination. This is often triggered by an infection, with Campylobacter jejuni being a common culprit. In the initial stages of the illness, around 65% of patients experience back or leg pain. However, the characteristic feature of Guillain-Barre syndrome is progressive, symmetrical weakness of all limbs, with the legs being affected first in an ascending pattern. Reflexes are reduced or absent, and sensory symptoms tend to be mild. Other features may include a history of gastroenteritis, respiratory muscle weakness, cranial nerve involvement, diplopia, bilateral facial nerve palsy, oropharyngeal weakness, and autonomic involvement, which can lead to urinary retention and diarrhea. Less common findings may include papilloedema, which is thought to be secondary to reduced CSF resorption. To diagnose Guillain-Barre syndrome, a lumbar puncture may be performed, which can reveal a rise in protein with a normal white blood cell count (albuminocytologic dissociation) in 66% of cases. Nerve conduction studies may also be conducted, which can show decreased motor nerve conduction velocity due to demyelination, prolonged distal motor latency, and increased F wave latency.

For patients who experience frequent and severe migraines, preventive treatment should be considered if acute treatments are ineffective or not suitable, or if there is a risk of medication-overuse headaches. Propranolol is the first-line prophylactic treatment, but if it is not suitable, alternative treatments such as topiramate or amitriptyline may be considered. Gabapentin should not be used for migraine prophylaxis. Non-pharmacological therapies such as acupuncture, relaxation techniques, or cognitive behavioural therapy can also be used as an alternative or adjunct to pharmacological therapy. Daily riboflavin may also be helpful in reducing migraine frequency and intensity. It is important to advise patients to limit their use of acute medication to a maximum of 2 days per week to avoid medication-overuse headaches. Referral for same-day neurology assessment is not necessary unless there are red-flag features. If the patient doesn’t respond to acupuncture, a neurology referral may be indicated.

Managing Migraines: Guidelines and Treatment Options

Migraines can be debilitating and affect a significant portion of the population. To manage migraines, it is important to understand the different treatment options available. The National Institute for Health and Care Excellence (NICE) has provided guidelines for the management of migraines.

For acute treatment, a combination of an oral triptan and an NSAID or paracetamol is recommended as first-line therapy. For young people aged 12-17 years, a nasal triptan may be preferred. If these measures are not effective or not tolerated, a non-oral preparation of metoclopramide or prochlorperazine may be offered, along with a non-oral NSAID or triptan.

Prophylaxis should be considered if patients are experiencing two or more attacks per month. NICE recommends either topiramate or propranolol, depending on the patient’s preference, comorbidities, and risk of adverse events. Propranolol is preferred in women of childbearing age as topiramate may be teratogenic and reduce the effectiveness of hormonal contraceptives. Acupuncture and riboflavin may also be effective in reducing migraine frequency and intensity.

For women with predictable menstrual migraines, frovatriptan or zolmitriptan may be used as a type of mini-prophylaxis. Specialists may also consider candesartan or monoclonal antibodies directed against the calcitonin gene-related peptide (CGRP) receptor, such as erenumab. However, pizotifen is no longer recommended due to common adverse effects such as weight gain and drowsiness.

It is important to exercise caution with young patients as acute dystonic reactions may develop. By following these guidelines and considering the various treatment options available, migraines can be effectively managed and their impact on daily life reduced.

For patients with type 2 diabetes who do not have chronic kidney disease, the recommended blood pressure targets are the same as for patients without diabetes. This means a clinic reading of less than 140/90 mmHg and an ambulatory or home blood pressure reading of less than 135/85 mmHg if the patient is under 80 years old. It’s important to note that even if the patient’s estimated glomerular filtration rate (eGFR) is below 90, this doesn’t necessarily mean they have CKD unless there is also evidence of microalbuminuria.

NICE has updated its guidance on the management of type 2 diabetes mellitus (T2DM) in 2022 to reflect advances in drug therapy and improved evidence regarding newer therapies such as SGLT-2 inhibitors. For the average patient taking metformin for T2DM, lifestyle changes and titrating up metformin to aim for a HbA1c of 48 mmol/mol (6.5%) is recommended. A second drug should only be added if the HbA1c rises to 58 mmol/mol (7.5%). Dietary advice includes encouraging high fiber, low glycemic index sources of carbohydrates, controlling intake of saturated fats and trans fatty acids, and initial target weight loss of 5-10% in overweight individuals.

Individual HbA1c targets should be agreed upon with patients to encourage motivation, and HbA1c should be checked every 3-6 months until stable, then 6 monthly. Targets should be relaxed on a case-by-case basis, with particular consideration for older or frail adults with type 2 diabetes. Metformin remains the first-line drug of choice, and SGLT-2 inhibitors should be given in addition to metformin if the patient has a high risk of developing cardiovascular disease (CVD), established CVD, or chronic heart failure. If metformin is contraindicated, SGLT-2 monotherapy or a DPP-4 inhibitor, pioglitazone, or sulfonylurea may be used.

Further drug therapy options depend on individual clinical circumstances and patient preference. Dual therapy options include adding a DPP-4 inhibitor, pioglitazone, sulfonylurea, or SGLT-2 inhibitor (if NICE criteria are met). If a patient doesn’t achieve control on dual therapy, triple therapy options include adding a sulfonylurea or GLP-1 mimetic. GLP-1 mimetics should only be added to insulin under specialist care. Blood pressure targets are the same as for patients without type 2 diabetes, and ACE inhibitors or ARBs are first-line for hypertension. Antiplatelets should not be offered unless a patient has existing cardiovascular disease, and only patients with a 10-year cardiovascular risk > 10% should be offered a statin.

Patients with cervical myelopathy should be managed by specialist spinal services, such as neurosurgery or orthopaedic spinal surgery. The main treatment for this condition is decompressive surgery, which is necessary to prevent further deterioration in cases of progressive or severe disease. Close observation may be an option for mild and stable disease, but surgery is required to stop disease progression.

It is important to note that pre-operative physiotherapy should only be initiated by specialist services, as manipulation can cause more spinal cord damage. The timing of surgery is crucial, as any existing spinal cord damage can be permanent. Treatment within 6 months offers the best chance of making a full recovery. Unfortunately, many patients wait more than 2 years for a diagnosis, highlighting the need for improved awareness and timely referral.

While neuropathic analgesia can provide symptomatic relief, it will not prevent further cord damage. Physiotherapy should not replace surgical opinion and should only be initiated by specialist services to avoid causing more spinal cord damage.

Degenerative cervical myelopathy (DCM) is a condition that has several risk factors, including smoking, genetics, and certain occupations that expose individuals to high axial loading. The symptoms of DCM can vary in severity and may include pain, loss of motor function, loss of sensory function, and loss of autonomic function. Early symptoms may be subtle and difficult to detect, but as the condition progresses, symptoms may worsen or new symptoms may appear. An MRI of the cervical spine is the gold standard test for diagnosing cervical myelopathy. All patients with DCM should be urgently referred to specialist spinal services for assessment and treatment. Decompressive surgery is currently the only effective treatment for DCM, and early treatment offers the best chance of a full recovery. Physiotherapy should only be initiated by specialist services to prevent further spinal cord damage.

The patient is experiencing symptoms of hypercalcaemia and has elevated calcium levels, indicating primary hyperparathyroidism. However, her parathyroid hormone levels are normal, which is unusual as they are typically decreased in the presence of high calcium levels. This rules out secondary hyperparathyroidism caused by another disease. Tertiary hyperparathyroidism is also unlikely as PTH levels would be significantly elevated. There is no indication of tuberculosis or bony metastasis, making primary hyperparathyroidism the most probable diagnosis.

Primary Hyperparathyroidism: Causes, Symptoms, and Treatment

Primary hyperparathyroidism is a condition that is commonly seen in elderly females and is characterized by an unquenchable thirst and an inappropriately normal or raised parathyroid hormone level. It is usually caused by a solitary adenoma, hyperplasia, multiple adenoma, or carcinoma. While around 80% of patients are asymptomatic, the symptomatic features of primary hyperparathyroidism may include polydipsia, polyuria, depression, anorexia, nausea, constipation, peptic ulceration, pancreatitis, bone pain/fracture, renal stones, and hypertension.

Primary hyperparathyroidism is associated with hypertension and multiple endocrine neoplasia, such as MEN I and II. To diagnose this condition, doctors may perform a technetium-MIBI subtraction scan or look for a characteristic X-ray finding of hyperparathyroidism called the pepperpot skull.

The definitive management for primary hyperparathyroidism is total parathyroidectomy. However, conservative management may be offered if the calcium level is less than 0.25 mmol/L above the upper limit of normal, the patient is over 50 years old, and there is no evidence of end-organ damage. Patients who are not suitable for surgery may be treated with cinacalcet, a calcimimetic that mimics the action of calcium on tissues by allosteric activation of the calcium-sensing receptor.

In summary, primary hyperparathyroidism is a condition that can cause various symptoms and is commonly seen in elderly females. It can be diagnosed through various tests and managed through surgery or medication.

Treatment options for Peripheral Arterial Disease (PAD)

Peripheral Arterial Disease (PAD) is a condition that causes intermittent claudication. Antiplatelet therapy is recommended for those with symptomatic disease to reduce major cardiovascular events. Clopidogrel is suggested as the drug of first choice by the National Institute for Health and Care Excellence (NICE). Angiotensin converting enzyme inhibitors have been shown to reduce cardiovascular morbidity and mortality in patients with PAD. However, they should be carefully monitored as more than 25% of patients have co-existent renal artery stenosis. Statins are also recommended as they reduce the risk of mortality, cardiovascular events and stroke in patients with PAD. Naftidrofuryl oxalate is an option for the treatment of intermittent claudication in people with PAD for whom vasodilator therapy is considered appropriate. Amlodipine, a calcium channel blocker, is not indicated for this case.

Bronchiectasis as a Possible Diagnosis for Chronic Non-Productive Cough

Consider bronchiectasis as a possible diagnosis for a patient with a chronic non-productive cough, especially if the patient is a non-smoker. While other diagnoses are also possible, bronchiectasis is more likely if the patient doesn’t exhibit symptoms such as night sweats, weight loss, or the growth of Pseudomonas. It is important to note that a chest X-ray may not always show abnormalities in patients with bronchiectasis, and a CT-scan is often necessary for an accurate diagnosis. Therefore, if a patient presents with a chronic non-productive cough, bronchiectasis should be considered as a possible diagnosis, particularly in non-smokers.

If a patient is allergic to penicillin, erythromycin is the preferred antibiotic for treating cellulitis during pregnancy. Clarithromycin, another macrolide antibiotic, is the alternative choice for penicillin-allergic patients, but it should be avoided during pregnancy.

Understanding Cellulitis: Symptoms, Diagnosis, and Treatment

Cellulitis is a common skin infection caused by Streptococcus pyogenes or Staphylococcus aureus. It is characterized by inflammation of the skin and subcutaneous tissues, usually on the shins, accompanied by erythema, pain, swelling, and sometimes fever. The diagnosis of cellulitis is based on clinical features, and no further investigations are required in primary care. However, bloods and blood cultures may be requested if the patient is admitted and septicaemia is suspected.

To guide the management of patients with cellulitis, NICE Clinical Knowledge Summaries recommend using the Eron classification. Patients with Eron Class III or Class IV cellulitis, severe or rapidly deteriorating cellulitis, very young or frail patients, immunocompromised patients, patients with significant lymphoedema, or facial or periorbital cellulitis (unless very mild) should be admitted for intravenous antibiotics. Patients with Eron Class II cellulitis may not require admission if the facilities and expertise are available in the community to give intravenous antibiotics and monitor the patient.

The first-line treatment for mild/moderate cellulitis is flucloxacillin, while clarithromycin, erythromycin (in pregnancy), or doxycycline is recommended for patients allergic to penicillin. Patients with severe cellulitis should be offered co-amoxiclav, cefuroxime, clindamycin, or ceftriaxone. Understanding the symptoms, diagnosis, and treatment of cellulitis is crucial for effective management and prevention of complications.

If a patient with stress incontinence doesn’t respond to pelvic floor muscle exercises and declines surgical intervention, duloxetine may be considered as a treatment option. However, it is important to first rule out other potential causes of urinary incontinence, such as infection. Non-pharmacological management, such as pelvic floor exercises and reducing caffeine intake, should be attempted before medical management. Duloxetine, a serotonin/norepinephrine reuptake inhibitor, is commonly used for stress incontinence but may cause side effects such as nausea, dizziness, and insomnia. For urge incontinence, antimuscarinic agents like oxybutynin, tolterodine, and solifenacin are typically used as first-line treatment. If these are ineffective, a β3 agonist called mirabegron can be used as a second-line therapy.

Urinary incontinence is a common condition that affects approximately 4-5% of the population, with elderly females being more susceptible. There are several risk factors that can contribute to the development of urinary incontinence, including advancing age, previous pregnancy and childbirth, high body mass index, hysterectomy, and family history. The condition can be classified into different types, such as overactive bladder, stress incontinence, mixed incontinence, overflow incontinence, and functional incontinence.

Initial investigation of urinary incontinence involves completing bladder diaries for at least three days, performing a vaginal examination to exclude pelvic organ prolapse, and conducting urine dipstick and culture tests. Urodynamic studies may also be necessary. Management of urinary incontinence depends on the predominant type of incontinence. For urge incontinence, bladder retraining and bladder stabilizing drugs such as antimuscarinics are recommended. For stress incontinence, pelvic floor muscle training and surgical procedures may be necessary. Duloxetine, a combined noradrenaline and serotonin reuptake inhibitor, may also be offered to women who decline surgical procedures.

In summary, urinary incontinence is a common condition that can be caused by various risk factors. It can be classified into different types, and management depends on the predominant type of incontinence. Initial investigation involves completing bladder diaries, performing a vaginal examination, and conducting urine tests. Treatment options include bladder retraining, bladder stabilizing drugs, pelvic floor muscle training, surgical procedures, and duloxetine.

Balanitis: Causes and Management

Balanitis is a common condition that presents in general practice. It can have various causes, but the most likely cause in many cases is an irritant reaction from excessive washing and use of soaps. Other common causes include Candida, psoriasis, and other skin conditions. If there is any discharge, swabbing should be done. If ulceration is present, herpes simplex virus (HSV) should be considered. In older men with persistent symptoms, Premalignant conditions and possible biopsy may be considered.

The management of balanitis involves advice, reassurance, and a topical steroid as the initial treatment. Testing for glycosuria should be considered to rule out Candida. If the symptoms persist, further investigation may be necessary to determine the underlying cause. It is important to identify the cause of balanitis to ensure appropriate management and prevent recurrence. By understanding the causes and management of balanitis, healthcare professionals can provide effective care to patients with this condition.

Treatment Options for Tennis Elbow: Managing Symptoms and Long-Term Prognosis

Tennis elbow, or lateral epicondylitis, is a painful condition that can be triggered by certain activities, such as lifting objects. The National Institute for Health and Care Excellence recommends modifying these activities to alleviate symptoms. However, in severe cases, other treatment options may be necessary.

Botulinum toxin A injections can be effective in paralyzing the affected fingers, but the resulting paralysis can significantly impact daily activities and is only recommended for severe cases. Corticosteroid injections can provide short-term pain relief, but the high relapse rate at three months makes them less suitable for long-term management.

Glyceryl trinitrate patches have shown short-term benefits in managing pain, but their long-term efficacy is uncertain. Ibuprofen may provide temporary pain relief, but it doesn’t affect the long-term prognosis. Overall, managing symptoms and preventing further injury through activity modification is the most important aspect of treating tennis elbow.

GP Refusal to Provide Abortion Information

Access to abortion is a controversial issue, and some GPs refuse to refer or provide information on abortion to their female patients due to their religious or moral beliefs. However, according to GMC guidance, doctors must not allow their personal beliefs to affect their ability to provide appropriate patient care. Therefore, a GP who objects to providing abortion information should be willing to refer their patient to another doctor in the practice who can provide the necessary information. It is important for doctors to prioritize their patients’ needs and ensure that they receive the care they require, regardless of their own personal beliefs.

NICE Guidance for Suspected Pancreatic, Gallbladder, and Liver Cancer

There is a growing concern about malignancy when a patient experiences weight loss, jaundice, and an abdominal mass. To address this issue, the latest NICE guidance recommends several actions.

Firstly, for patients aged 40 and over with jaundice, healthcare professionals should refer them using a suspected cancer pathway referral for an appointment within two weeks to assess for pancreatic cancer. Secondly, for patients with an upper abdominal mass consistent with an enlarged Gallbladder, healthcare professionals should consider an urgent direct access ultrasound scan to assess for Gallbladder cancer within two weeks. Lastly, for patients with an upper abdominal mass consistent with an enlarged liver, healthcare professionals should consider an urgent direct access ultrasound scan to assess for liver cancer within two weeks.

By following these guidelines, healthcare professionals can quickly identify and address potential cancer diagnoses, improving patient outcomes and quality of life.

NSAIDs and Gastrointestinal Bleeds: Risk Factors and Mechanisms

Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for pain relief and inflammation management. However, their use is associated with an increased risk of gastrointestinal bleeds, particularly in patients with pre-existing gastric or duodenal ulcers. Even those without a history of ulcers are at risk, with the relative risk varying among different NSAID preparations. NSAIDs directly damage the gastric mucosal barrier by depleting mucosal PGE levels, which decreases the gastroduodenal defence mechanisms and cytoprotective effect of PGE, resulting in mucosal injury, erosions and ulceration.

Several factors increase the risk of ulceration in the setting of NSAID use, including previous peptic ulcer disease, advanced age, female sex, high doses or combinations of NSAIDs, long-term NSAID use, concomitant use of anticoagulants, and severe comorbid illnesses. Even low-dose aspirin, with increasing use, is a major cause of upper gastrointestinal problems, particularly bleeding. It is important to note that NSAIDs may have adverse effects in all parts of the gastrointestinal tract, not only the stomach or duodenum; the oesophagus, small intestine and colon may also be affected. Endoscopic evidence of peptic ulceration is found in 20% of NSAID users even in the absence of symptoms.

In conclusion, while NSAIDs are effective in managing pain and inflammation, their use is associated with an increased risk of gastrointestinal bleeds. Patients with pre-existing gastric or duodenal ulcers are particularly at risk, but other factors such as advanced age, high doses or combinations of NSAIDs, and concomitant use of anticoagulants also increase the risk. It is important to weigh the benefits and risks of NSAID use and consider alternative pain management strategies in high-risk patients.

After a heart attack, it is safe to resume sexual activity after a period of 4 weeks.

Myocardial infarction (MI) is a serious condition that requires proper management to prevent further complications. The National Institute for Health and Care Excellence (NICE) has provided guidelines for the secondary prevention of MI. Patients who have had an MI should be offered dual antiplatelet therapy, ACE inhibitors, beta-blockers, and statins. Lifestyle changes such as following a Mediterranean-style diet and engaging in regular exercise are also recommended. Sexual activity may resume after four weeks, and PDE5 inhibitors may be used after six months, but caution should be exercised in patients taking nitrates or nicorandil.

Dual antiplatelet therapy is now the standard treatment for most patients who have had an acute coronary syndrome. Ticagrelor and prasugrel are now more commonly used as ADP-receptor inhibitors. The NICE Clinical Knowledge Summaries recommend adding ticagrelor to aspirin for medically managed patients and prasugrel or ticagrelor for those who have undergone percutaneous coronary intervention. The second antiplatelet should be stopped after 12 months, but this may be adjusted for patients at high risk of bleeding or further ischaemic events.

For patients who have had an acute MI and have symptoms and/or signs of heart failure and left ventricular systolic dysfunction, treatment with an aldosterone antagonist such as eplerenone should be initiated within 3-14 days of the MI, preferably after ACE inhibitor therapy. Proper management and adherence to these guidelines can significantly reduce the risk of further complications and improve the patient’s quality of life.

Understanding Different Types of Dementia: Differential Diagnosis for Memory Impairment

Memory impairment is a common symptom in older adults, and it can be caused by various conditions, including dementia. Dementia affects approximately 5% of people over 65 and 20% of individuals over 80. Alzheimer’s disease is the most common cause of dementia, accounting for around 60% of cases. However, other types of dementia should also be considered in the differential diagnosis.

Depression is an important differential diagnosis in an older person presenting with memory impairment. Apathy and disconnection with activities that the patient previously enjoyed are common symptoms of depression. Mild cognitive impairment (MCI) is another condition that can cause memory impairment. However, MCI is characterized by memory impairment with preservation of other cognitive domains and intact activities of daily living.

Lewy-body dementia is a type of dementia that accounts for approximately 20% of cases. It usually presents with parkinsonism, fluctuating cognitive impairment, and visual hallucinations. Vascular dementia (vascular cognitive impairment) is another type of dementia caused by cerebrovascular disease. It is a progressive disease where deteriorations may be sudden or gradual but tend to progress in a stepwise manner.

In this case, the patient’s mini-mental state examination result supports the diagnosis of Alzheimer’s disease. The patient (or their relatives) commonly complains of difficulty with common activities of daily living and short-term memory loss. It is important to consider all possible causes of memory impairment to provide appropriate treatment and support for patients and their families.

Although febrile seizures are frequent, it is crucial to have a pediatrician confirm the diagnosis and exclude any serious underlying condition. Therefore, according to NICE clinical knowledge summaries, if a child experiences their initial febrile seizure, they must be promptly hospitalized and assessed by a pediatrician.

It would be inappropriate to merely reassure the mother or postpone the evaluation until the following day. An antibiotic allergy would not typically trigger a seizure.

Febrile convulsions are seizures that occur in otherwise healthy children when they have a fever. They are most common in children between the ages of 6 months and 5 years, affecting around 3% of children. Febrile convulsions usually occur at the onset of a viral infection when the child’s temperature rises rapidly. The seizures are typically brief, lasting less than 5 minutes, and are usually tonic-clonic in nature.

There are three types of febrile convulsions: simple, complex, and febrile status epilepticus. Simple febrile convulsions last less than 15 minutes and are generalised seizures. Complex febrile convulsions last between 15 and 30 minutes and may be focal seizures. Febrile status epilepticus lasts for more than 30 minutes. Children who have had their first seizure or any features of a complex seizure should be admitted to paediatrics.

Following a seizure, parents should be advised to call an ambulance if the seizure lasts longer than 5 minutes. Regular antipyretics have not been shown to reduce the chance of a febrile seizure occurring. If recurrent febrile convulsions occur, benzodiazepine rescue medication may be considered, but this should only be started on the advice of a specialist, such as a paediatrician. Rectal diazepam or buccal midazolam may be used.

The overall risk of further febrile convulsions is 1 in 3, but this varies depending on risk factors for further seizure. These risk factors include age of onset under 18 months, fever below 39ºC, shorter duration of fever before the seizure, and a family history of febrile convulsions. Children with no risk factors have a 2.5% risk of developing epilepsy, while those with all three risk factors have a much higher risk of developing epilepsy, up to 50%.

According to the British National Formulary, the combination of methotrexate and antibiotics containing trimethoprim can lead to bone marrow suppression and potentially fatal pancytopenia. Therefore, it is advised to avoid prescribing these two medications together. There are no reported interactions between methotrexate and the other listed medications.

Methotrexate is an antimetabolite that hinders the activity of dihydrofolate reductase, an enzyme that is crucial for the synthesis of purines and pyrimidines. It is a significant drug that can effectively control diseases, but its side-effects can be life-threatening. Therefore, careful prescribing and close monitoring are essential. Methotrexate is commonly used to treat inflammatory arthritis, especially rheumatoid arthritis, psoriasis, and acute lymphoblastic leukaemia. However, it can cause adverse effects such as mucositis, myelosuppression, pneumonitis, pulmonary fibrosis, and liver fibrosis.

Women should avoid pregnancy for at least six months after stopping methotrexate treatment, and men using methotrexate should use effective contraception for at least six months after treatment. Prescribing methotrexate requires familiarity with guidelines relating to its use. It is taken weekly, and FBC, U&E, and LFTs need to be regularly monitored. Folic acid 5mg once weekly should be co-prescribed, taken more than 24 hours after methotrexate dose. The starting dose of methotrexate is 7.5 mg weekly, and only one strength of methotrexate tablet should be prescribed.

It is important to avoid prescribing trimethoprim or co-trimoxazole concurrently as it increases the risk of marrow aplasia. High-dose aspirin also increases the risk of methotrexate toxicity due to reduced excretion. In case of methotrexate toxicity, the treatment of choice is folinic acid. Overall, methotrexate is a potent drug that requires careful prescribing and monitoring to ensure its effectiveness and safety.

Treatment Options for Osteoporosis

Osteoporosis is a condition that weakens bones, making them fragile and more likely to break. It is most common in postmenopausal women. Alendronate is a recommended treatment for preventing bone fractures in postmenopausal women who have already had a fracture and have been diagnosed with osteoporosis. Bisphosphonates are the most appropriate initial treatment for osteoporosis, as long as the estimated glomerular filtration rate (eGFR) is not below 35.

For patients who are unable to take bisphosphonates or other treatments, or in those with severe osteoporosis as defined by T-score, strontium ranelate was recommended as an alternative. However, the manufacturers stopped supplying it to the UK in August 2017. Teriparatide, a parathyroid hormone (PTH) analogue, is reserved for use in the most severely osteoporotic patient group. It is important to note that any treatment should be started after a full cardiovascular risk assessment.

Safeguarding Children in Healthcare

Safeguarding children has undergone significant changes in recent years, following the Children Act 2004 and the Victoria Climbié Inquiry. As a result, healthcare professionals must navigate a complex landscape of guidance documents, terminology, and organizational changes. The Royal College of General Practitioners offers a useful toolkit for those seeking an introduction to the topic.

According to the General Medical Council, the safety of children and young people must be a healthcare professional’s first concern. If there is reasonable concern that a child is at risk of abuse or neglect, the appropriate person or authority must be informed promptly. If there is no cause for concern, it is still important to discuss and record the decision, as well as any concerns, discussions, and reasons for not sharing information.

While confidentiality is important, it can be breached in limited circumstances, such as safeguarding children at risk. Healthcare professionals must avoid making discreet enquiries, as this can lead to unfounded rumors, breaches of confidentiality, and potentially prejudicing further enquiries. Overall, safeguarding children is a critical responsibility for healthcare professionals, and they must stay informed and vigilant in their efforts to protect vulnerable children.